TriangleWS-CART-CS1 (NCT06185751)
WS-CART-CS1 trial for Multiple Myeloma (NCT06185751). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
Multiple myeloma remains incurable, and responses to CAR T therapy aimed at one target, BCMA, often do not last.
The idea: aim CAR T cells at a different target, CS1, also called SLAMF7, which is found in most patients with myeloma. The patient's own T cells are collected and engineered with a CS1 receptor. They are returned after three days of chemotherapy that lowers existing lymphocytes. Patients stay in the hospital for seven days.
This early study looks at safety first, and at early signs of effect. At Washington University in St. Louis, Armin Ghobadi leads it.
Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.